Israeli Ministry Of Health Approves Can-Fite Biopharma's Phase 2A Clinical Trial With Orally-administered Namodenoson In The Treatment Of Pancreatic Carcinoma, Study Will Aim To Establish Safety And Clinical Efficacy
Portfolio Pulse from Benzinga Newsdesk
The Israeli Ministry of Health has approved Can-Fite Biopharma's Phase 2A clinical trial for Namodenoson, an orally-administered drug, in the treatment of pancreatic carcinoma. The study will focus on establishing the safety and clinical efficacy of the drug.
September 16, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Can-Fite Biopharma has received approval from the Israeli Ministry of Health to conduct a Phase 2A clinical trial for Namodenoson in treating pancreatic carcinoma. This approval is a positive step towards establishing the drug's safety and efficacy.
The approval for a Phase 2A trial is a significant milestone for Can-Fite Biopharma, as it allows the company to further test Namodenoson's safety and efficacy in treating pancreatic carcinoma. This regulatory approval is likely to be viewed positively by investors, potentially boosting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90